Abstract:Despite recent advances in cancer treatment, only 20-40% of all patients respond to immunotherapy. Further, efficacy varies highly by tumor type. Tumors with high infiltration of canonically anti-tumoral immune cells, such as lung cancers, also tend to display increased sensitivity to treatment. In contrast, those with higher infiltration of pro-tumoral immune cells, such as pancreatic cancers, are much less amenable to immunotherapy. These differences in immune infiltration have been linked to differential transcriptional regulation of immune cell recruiting factors, suggesting that perhaps tumors can intrinsically assemble different immune microenvironments in a tissue-of-origin dependent manner. Thus, it is necessary to better understand the factors that lead to heterogeneity of immune cell infiltration, how these mechanisms differ across tumor types, and how they may be perturbed to improve therapy responses. Here, we utilized two panels of clonal cell lines both driven by Kras-G12D and Tp53-R172H mutations but derived from two different tissues of origin: the lung and pancreas. These panels serve to recapitulate the immune heterogeneity of non-small cell lung cancer and pancreatic ductal adenocarcinoma, respectively, while controlling for genetic drivers that may influence immune infiltration. Analyses of subcutaneously implanted lung and pancreatic-origin tumors revealed that the overall abundance of immunosuppressive granulocytic myeloid-derived suppressor cells (gMDSCs) is significantly higher in pancreatic-origin tumors while the infiltration of dendritic cells is much lower as compared to that of lung-origin tumors, despite controlling for engraftment site. Likewise, lung, but not pancreatic-origin tumors exhibit more rapid tumor growth upon natural killer (NK) cell depletion, suggesting a lung-origin specific role of NK cells in controlling tumor burden. There were also similarities in immune archetype, with T-cell abundance negatively correlating with that of gMDSCs. However, whereas "T-cell inflamed" pancreatic tumors partially respond to immune checkpoint blockade, their lung-origin counterparts do not. We hypothesized that these differences in immune phenotype and subsequent therapy response may be due in part to somatic copy number alterations (SCNAs). We performed sparse whole genome sequencing and identified substantial genomic rearrangements in both lung and pancreatic-origin tumors. Notably, the specific regions of rearrangements differed highly between the two panels, with lung-origin clones showing more amplifications in chromosomes 2 and 11 and deletions in chromosomes 16 and 18. These results suggest that there are indeed tissue-of-origin specific differences in immune phenotype that can influence therapy outcome. Ongoing work seeks to further elucidate specific tumor cell-intrinsic factors that can be leveraged to skew the tumor immune microenvironment towards a more anti-tumoral phenotype and ultimately increase sensitivity to immunotherapy in a site-specific manner. Citation Format: Jane Xie, Timour Baslan, Ben Stanger. Tissue-of-origin determines immune cell heterogeneity and response to therapy via unique tumor cell-intrinsic factors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A046.

Tissue specificity of oncogenic BRAF targeted to lung and thyroid through a shared lineage factor

Alveolar Type Ii Cells Possess The Capability Of Initiating Lung Tumor Development

Nkx2-1: a Novel Tumor Biomarker of Lung Cancer

BRAF V600E Mutation and the Bethesda System for Reporting Thyroid Cytopathology of Fine-Needle Aspiration Biopsy for Distinguishing Benign from Malignant Thyroid Nodules

An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma

Tissue-location-specific transcription programs drive tumor dependencies in colon cancer

SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies

Abstract 3591: Upregulation of CXCL8 is an early step in the oncogenic transition of human thyroid cells by BRAFV600E

Single nuclei and spatial transcriptomes suggest a stratification of papillary and anaplastic thyroid cancer cells

Abstract A046: Tissue-of-origin determines immune cell heterogeneity and response to therapy via unique tumor cell-intrinsic factors

BRAFV600E promotes anchorage-independent growth but inhibits anchorage-dependent growth in hTERT/Cdk4-Immortalized normal human bronchial epithelial cells

Proteostatic reactivation of the developmental transcription factor TBX3 drives BRAF/MAPK-mediated tumorigenesis

Opposing lineage specifiers induce a pro-tumor hybrid-identity state in lung adenocarcinoma

The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2.

Papillary thyroid cancer organoids harboring BRAF V600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

Pan-cancer Analysis of BRAF Alterations and Tumor-Specific Mechanisms of Activation.

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Abstract LB050: BRAF V600E is associated with the upregulation of CLDN1 in thyroid cancer

Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression.

Abstract 6997: Elucidating the tumorigenic properties of alveolar epithelial type 1 cells in EGFR-mediated LUAD tumorigenesis

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2